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Abstract
The pathways downstream of the epidermal growth factor receptor (EGFR) have often been implicated to play
crucial roles in the development and progression of various cancer types. Different authors have proposed models
in cell lines in which they study the modes of pathway activities after perturbation experiments. It is prudent to
believe that a better understanding of these pathway activation patterns might lead to novel treatment concepts
for cancer patients or at least allow a better stratification of patient collectives into different risk groups or into
groups that might respond to different treatments. Traditionally, such analyses focused on the individual players of
the pathways. More recently in the field of systems biology, a plethora of approaches that take a more holistic
view on the signaling pathways and their downstream transcriptional targets has been developed. Fertig et al.
have recently developed a new method to identify patterns and biological process activity from transcriptomics
data, and they demonstrate the utility of this methodology to analyze gene expression activity downstream of the
EGFR in head and neck squamous cell carcinoma to study cetuximab resistance. Please see related article: http://
www.biomedcentral.com/1471-2164/13/160
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Background
The epidermal growth factor receptor (EGFR) is a trans-
membrane receptor belonging to the group of receptor
tyrosine kinases that forward extracellular signals via
phosphorylation cascades, which finally arouse cellular
responses. This kind of proteins is often related to can-
cer due to mutations or overexpression leading to aber-
rant signaling and resultant excessive proliferation [1-3].
Main adaptors for EGFR are GRB2 and Shc, activating
the mitogen-activated protein kinase (MAPK) pathway
v i aR A S .E R B B 2b i n d i n gs i t e sa r em o r ep r o m i s c u o u s ,
enabling the respective dimers to activate not only the
MAPK but also the phosphoinositide 3-kinase (PI3K)
pathway, the two major pathways in ERBB signaling
responsible for cell proliferation, cellular survival and
anti-apoptosis [4]. Also, cross-talk of these pathways
exists, offering potential bypass strategies in the protein
network (Figure 1). Due to the association of overex-
pressed EGFR with poor prognosis of head and neck
squamous cell carcinoma (HNSCC), cetuximab, a mono-
clonal antibody targeting the receptor, is applied in com-
mon therapeutic strategies [5]. However, many HNSCC
patients are non-responders or develop resistance, which
is suspected to result from aberrant activation of EGFR
pathways [6,7]. To improve such a targeted therapy, it
would be beneficial to gain insight into the individual
molecular specificity of the targeted pathway per patient
[8]. Thus, in a personalized medicine approach, the rele-
vance of the pathway should be revealed in advance to
treatment. Therefore, the detection of common gene
activity patterns among sample subsets is used to stratify
patients based on their gene expression profiles.
Gene expression microarrays are a widely used tool to
measure genomewide transcription within cell lines or
tissues under varying conditions. Usually, gene-wise
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are then performed to determine differentially expressed
genes [9]. Methods to find overrepresentation of func-
tional gene sets or pathway genes, so called gene set
enrichment analysis (GSEA), are employed in order to
interpret the resulting long lists of differential genes
[10-12]. To monitor the activity of certain pathway parts
or transcription factors (TFs), gene sets of TF target
genes, as they can be retrieved from databases like
TRANSFAC, are of special interest [13]. Another aspect
of data analysis is revealing gene expression patterns of
patient or gene groups by clustering or dimension
reduction techniques [14]. A number of specialized
methods have been proposed previously, for example,
clustering genes and patients simultaneously into biclus-
ters [15], applying predefined gene signatures in guided
clustering approaches [16] or signal flow reconstruction
in pathways from downstream effects of perturbation
experiments [17].
Fertig et al. have proposed the new method Coordi-
nated Gene Activity in Pattern Sets (CoGAPS) [18] and
made it available as add-on for the popular free statisti-
cal computing software R [19]. It combines a matrix fac-
torization technique with GSEA of downstream
transcriptional targets to determine patterns of pathway
activity. They now demonstrate its utility to study cetux-
imab resistance in HNSCC by analyzing gene expression
patterns downstream of EGFR [20].
Discussion
Fertig et al. present a modeling approach of cetuximab
resistance mechanisms applying the CoGAPS algorithm
to infer gene expression signatures, distinguishing five
variants of HaCaT cell lines under different media condi-
tions concerning serum starvation and addition of EGF
or TNF-a. These immortalized keratinocytes are chosen
as model systems as they are well characterized and their
genetic aberrations reflect early oncogenic events in
Figure 1 Signaling pathways involved in head and neck cancer. The main pathways contributing to signaling in head and neck cancer, that
is, NOTCH, RAS, AKT, TGF-b and STAT, are depicted in an abstract manner including only most relevant cellular components in this context.
Activation is induced via binding of ligands to extracellular receptor parts, resulting in intracellular phosphorylation cascades leading to
transcription of certain gene sets (numbers correspond to gene set sizes in Fertig et al. [20]) related to individual transcription factors or whole
pathways (total number of targets quoted in brackets).
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to compare two isogenic HNSCC cell lines, that is,
UMSCC1 and 1CC8, of which the latter is known to be
cetuximab resistant in contrast to the sensitive UMSCC1
cell line.
The CoGAPS method
This method factorizes the input gene expression data
matrix, with genes as rows and experimental conditions
as columns, into two matrices, one defining different
patterns of conditions and one storing amplitudes indi-
cating the involvement strength of the respective gene
in each pattern (Figure 2). The second step of CoGAPS
then is to use the input list of gene sets, namely path-
way-related TFs and their targets, to calculate Z-scores
determining pattern-specific pathway activity. Thus, the
required inputs are the mean gene expression data per
experimental condition, the estimated standard devia-
tions from replicates, a list of gene sets for TF targets,
hyperparameters indicating the sparsity of the pattern
and amplitude matrices and, finally, the number of pat-
terns to be inferred. The outputs are the activity levels
of the different experimental conditions per pattern,
individual gene activity per pattern and enrichment
scores for gene set activities in each pattern.
Analysis of EGFR downstream activation patterns on
HNSCC data
The HaCaT variants include transfected cell types over-
expressing EGFR, NF-kappa-B p65 subunit or mutant
HRAS. Transcriptional targets of sub-pathways under
investigation belong to STAT, AKT, RAS, Notch and
TGF-b due to their implication in HNSCC. Applying
CoGAPS to the HaCaT gene expression data reveals six
patterns, which separate the samples well according to
their experimental conditions. Thus, the patterns are
attributed to baseline HaCaT activity, HaCaT-HRAS-
Val12, HaCaT-vector control, HaCaT-EGFR
WT,s e r u m
and HaCaT-p65
WT. Afterwards, the activities of down-
stream transcriptional targets are calculated based on
the Z-scores. This confirms upregulation of expected
pathways but also indicates potential cross-talk mechan-
isms. The method is compared to a standard linear
model approach with outcomes less consistent with
prior knowledge. For example, CoGAPS reveals RAS
and STAT overrepresentation for forced HRAS and
EGFR expression in HaCaT cells and assigns Notch
activity to the baseline pattern. Finally, the CoGAPS pat-
terns are projected to the gene expression data of
UMSCC1 and 1CC8 with and without cetuximab treat-
ment. The most interesting finding here is that the
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Figure 2 Scheme of CoGAPS algorithm. In the first step, CoGAPS factorizes the gene expression data matrix (D) into the amplitude (A) and
pattern (P) matrices. The pattern matrix summarizes common expression patterns among different experimental conditions. The amplitude
matrix summarizes the gene expression activity of all genes in the specified patterns. In the second step, the expression activity from matrix A is
analyzed for pattern-specific pathway activation. This is done by testing for enriched activity of gene sets of transcription factor targets.
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Val12
could predict the cetuximab treatment response, that is,
treatment reduces the signature amplitude in sensitive
UMSCC1, but not in resistant 1CC8. This is interpreta-
ble in such a way that cetuximab fails to repress the
hyperactive RAS pathway in resistant HNSCC cell lines.
A possible extension of this for the future would be to
apply the learned signature to patient data and test
whether it is likewise able to predict clinical parameters
such as treatment response.
Conclusions
The main drawback of established techniques to infer
activity of gene sets, clustering for example, is that they
are neglecting multiple regulation of genes, that is, gene
re-usage and co-regulation by diverse pathways and TFs
as well as coordinated activity of gene sets, for example,
pathway cross-talk, which actually constitutes a specific
phenotype. To overcome this disadvantage, the CoGAPS
algorithm focuses on gene sets instead of isolated genes
for inferring biological processes based on transcriptional
data. The multitude of computational methods and tools
analyzing activity patterns of (interacting) pathways should
be further developed and compared to each other in the
future. The presented results indicate the potential of the
CoGAPS algorithm to detect transcriptional signatures as
biomarkers for individual drug sensitivity or resistance,
respectively. These signatures will have to be tested and
prove their value in clinical practice in the future.
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